INNOVIVA, INC. Proceeds from Debt, Net of Issuance Costs
INNOVIVA, INC. (INVA) reported Proceeds from Debt, Net of Issuance Costs of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2017-02-28
- INNOVIVA, INC. proceeds from debt, net of issuance costs for the quarter ending 2015-12-31 was $0.00.
- INNOVIVA, INC. proceeds from debt, net of issuance costs for the quarter ending 2015-09-30 was $0.00.
- INNOVIVA, INC. proceeds from debt, net of issuance costs for the quarter ending 2014-12-31 was $0.00.
- INNOVIVA, INC. proceeds from debt, net of issuance costs for the quarter ending 2014-09-30 was $0.00.
- INNOVIVA, INC. proceeds from debt, net of issuance costs for fiscal 2016 was $0.00.
- INNOVIVA, INC. proceeds from debt, net of issuance costs for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- INNOVIVA, INC. proceeds from debt, net of issuance costs for fiscal 2014 was $434.68M, a 54.35% increase from fiscal 2013.
- INNOVIVA, INC. proceeds from debt, net of issuance costs for fiscal 2013 was $281.62M.
| Period end | Proceeds from Debt, Net of Issuance Costs 3 month | Proceeds from Debt, Net of Issuance Costs 6 month | Proceeds from Debt, Net of Issuance Costs 9 month | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-02-28 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $0.00 derived: sum of 2 quarters · filed 2017-02-28 | $0.00 10-K · filed 2017-02-28 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $0.00 10-Q · filed 2015-11-05 | ||
| 2015-06-30 | $0.00 10-Q · filed 2015-08-06 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $0.00 derived: sum of 2 quarters · filed 2017-02-28 | $434.68M 10-K · filed 2017-02-28 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $434.68M 10-Q · filed 2015-11-05 | ||
| 2014-06-30 | $434.68M 10-Q · filed 2015-08-06 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $281.62M 10-K · filed 2016-02-24 | ||
| 2013-09-30 | $281.62M 10-Q · filed 2014-11-04 | |||
| 2012-12-31 | -$441.00K 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |